Food contact materials as possible endocrine disruptors for PPARs: a consensus scoring analysis

References

• Barroso E, Rodríguez-Calvo R, Serrano-Marco L, Astudillo AM, Balsinde J, Palomer X, Vázquez-Carrera M. 2011. The PPARβ/δ Activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1α-lipin 1-PPARα pathway leading to increased fatty acid oxidation. Endocrinology. 152(5):1848–1859.
   PubMed Web of Science ®Google Scholar
• Botta M, Audano M, Sahebkar A, Sirtori C, Mitro N, Ruscica M. 2018. PPAR agonists and metabolic syndrome: an established role? Int J Mol Sci. 19(4):1197.
   PubMed Web of Science ®Google Scholar
• Casals-Casas C, Desvergne B. 2011. Endocrine disruptors: from endocrine to metabolic disruption. Annu Rev Physiol. 73(1):135–162.
   PubMed Web of Science ®Google Scholar
• Corton JC, Anderson SP, Stauber A. 2000. Central Role of Peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu Rev Pharmacol Toxicol. 40(1):491–518.
   PubMedGoogle Scholar
• Delfosse V, Maire A. l, Balaguer P, Bourguet W. 2015. A structural perspective on nuclear receptors as targets of environmental compounds. Acta Pharmacol Sin. 36(1):88–101.
   PubMed Web of Science ®Google Scholar
• Desvergne B, Feige JN, Casals-Casas C. 2009. PPAR-mediated activity of phthalates: a link to the obesity epidemic? Mol Cell Endocrinol. 304(1–2):43–48.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, Zoeller RT, Gore AC. 2009. Endocrine-disrupting chemicals: an endocrine society scientific statement. Endocr Rev. 30(4):293–342.
   PubMed Web of Science ®Google Scholar
• Dubois V, Eeckhoute J, Lefebvre P, Staels B. 2017. Distinct but complementary contributions of PPAR isotypes to energy homeostasis. J Clin Invest. 127(4):1202–1214.
   PubMed Web of Science ®Google Scholar
• Eckel RH, Grundy SM, Zimmet PZ. 2005. The metabolic syndrome. Lancet. 365(9468):1415–1428.
   PubMed Web of Science ®Google Scholar
• Eugene Kellogg G, Abraham DJ. 2000. Hydrophobicity: is LogPo/w more than the sum of its parts? Eur J Med Chem. 35(7–8):651–661.
   PubMed Web of Science ®Google Scholar
• Feige JN, Gelman L, Rossi D, Zoete V, Métivier R, Tudor C, Anghel SI, Grosdidier A, Lathion C, Engelborghs Y, et al. 2007. The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis. J Biol Chem. 282(26):19152–19166.
   PubMed Web of Science ®Google Scholar
• Ferre P. 2004. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes. 53(1):S43–S50.
   PubMedGoogle Scholar
• Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 1995. 15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell. 83(5):803–812.
   PubMed Web of Science ®Google Scholar
• Gottlicher M, Widmark E, Li Q, Gustafsson JA. 1992. Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA. 89(10):4653–4657.
   PubMed Web of Science ®Google Scholar
• Grob K. 2002. Comprehensive analysis of migrates from food-packaging materials: a challenge. Food Addit Contamin. 19(1):185–191.
   PubMedGoogle Scholar
• Hurst CH, Waxman DJ. 2003. Activation of PPARalpha and PPARgamma by environmental phthalate monoesters. Toxicol Sci. 74(2):297–308.
   PubMed Web of Science ®Google Scholar
• Kesäniemi YA, Grundy SM. 1984. Influence of femfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. JAMA. 251(17):2241–2246.
   PubMed Web of Science ®Google Scholar
• Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, Gonzalez FJ. 1995. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol. 15(6):3012–3022.
   PubMed Web of Science ®Google Scholar
• Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 270(22):12953–12956.
   PubMed Web of Science ®Google Scholar
• Michalik L, Desvergne B, Dreyer C, Gavillet M, Laurini RN, Wahli W. 2002. PPAR expression and function during vertebrate development. Int J Dev Biol. 46:105–114.
   Google Scholar
• Monsalve FA, Pyarasani RD, Delgado-Lopez F, Moore-Carrasco R. 2013. Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. Mediators Inflamm. 2013:549627–549618.
   PubMed Web of Science ®Google Scholar
• Muncke J. 2011. Endocrine disrupting chemicals and other substances of concern in food contact materials: an updated review of exposure, effect and risk assessment. J Steroid Biochem Mol Biol. 127(1–2):118–127.
   PubMed Web of Science ®Google Scholar
• Nettles KW, Greene GL. 2005. Ligand control of coregulator recruitment to nuclear receptors. Annu Rev Physiol. 67(1):309–333.
   PubMedGoogle Scholar
• Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, Moras D. 1995. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature. 378(6558):681–689.
   PubMed Web of Science ®Google Scholar
• Russell AP. 2004. Lipotoxicity: the obese and endurance-trained paradox. Int J Obes. 28(S4):S66–S71.
   Google Scholar
• Schoonjans K, Staels B, Auwerx J. 1996. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta. 1302(2):93–109.
   PubMedGoogle Scholar
• Shaffer RM, Ferguson KK, Sheppard L, James-Todd T, Butts S, Chandrasekaran S, Swan SH, Barrett ES, Nguyen R, Bush N, TIDES Study team, et al. 2019. Maternal urinary phthalate metabolites in relation to gestational diabetes and glucose intolerance during pregnancy. Environ Int. 123:588–596.
   PubMed Web of Science ®Google Scholar
• Shulman GI. 2000. Cellular mechanisms of insulin resistance. J Clin Invest. 106(2):171–176.
   PubMed Web of Science ®Google Scholar
• Tabb MM, Blumberg B. 2006. New modes of action for endocrine-disrupting chemicals. Mol Endocrinol. 20(3):475–482.
   PubMedGoogle Scholar
• Vázquez-Carrera M. 2016. Unraveling the effects of PPARβ/δ on insulin resistance and cardiovascular disease. Trends Endocrinol Metab. 27(5):319–334.
   PubMed Web of Science ®Google Scholar
• Wams T. 1987. Diethylhexylphthalate as an environmental contaminant — A review. Sci Total Environ. 66:1–16.
   PubMed Web of Science ®Google Scholar
• Wang L, Waltenberger B, Pferschy-Wenzig E-M, Blunder M, Liu X, Malainer C, Blazevic T, Schwaiger S, Rollinger JM, Heiss EH, et al. 2014. Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review. Biochem Pharmacol. 92(1):73–89.
   PubMed Web of Science ®Google Scholar
• Zoete V, Grosdidier A, Michielin O. 2007. Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta. 1771(8):915–925.
   PubMed Web of Science ®Google Scholar